EP300 and cancer: Studies have indicated that reader bromodomain inhibitors are only effective against a limited range of substrates acetylated by p300/CBP12,23, while the recently developed p300/CBP selective HAT domain inhibitor, A485, exhibited poor drug-like characteristics and modest effects on suppression of cancer cell proliferation20,24.